Literature DB >> 31504307

Cascade of Care for Alaska Native People With Chronic Hepatitis C Virus Infection: Statewide Program With High Linkage to Care.

Brian J Mcmahon1,2, Lisa Townshend-Bulson1, Chriss Homan1, Prabhu Gounder2, Youssef Barbour1, Annette Hewitt1, Dana Bruden2, Hannah Espera1, Julia Plotnik1, James Gove1, Timothy J Stevenson1, Sarah V Luna1, Brenna C Simons1,2.   

Abstract

Most persons with chronic hepatitis C virus (HCV) infection in the United States are undiagnosed or linked to care. We describe a program for the management of Alaska Native patients infection utilizing a computerized registry and statewide liver clinics resulting in higher linkage to care (86%) than national estimates (~25%).
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Alaska Natives; hepatitis C virus; linkage to care and treatment

Year:  2020        PMID： 31504307      PMCID： PMC7047515          DOI： 10.1093/cid/ciz832

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  12 in total

1.  Achievement of hepatitis C cascade of care milestones: a population-level analysis in Alberta, Canada.

Authors:  Conar R O'Neil; Emily Buss; Sabrina Plitt; Mariam Osman; Carla S Coffin; Carmen L Charlton; Stephen Shafran
Journal:  Can J Public Health       Date:  2019-06-20

2.  Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort.

Authors:  Dana J T Bruden; Brian J McMahon; Lisa Townshend-Bulson; Prabhu Gounder; Jim Gove; Julia Plotnik; Chriss Homan; Annette Hewitt; Youssef Barbour; Philip R Spradling; Brenna C Simons; Susan McArdle; Michael Bruce
Journal:  Hepatology       Date:  2017-05-22       Impact factor: 17.425

3.  Toward a more accurate estimate of the prevalence of hepatitis C in the United States.

Authors:  Brian R Edlin; Benjamin J Eckhardt; Marla A Shu; Scott D Holmberg; Tracy Swan
Journal:  Hepatology       Date:  2015-08-25       Impact factor: 17.425

Review 4.  Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

Authors: 
Journal:  Hepatology       Date:  2015-08-04       Impact factor: 17.425

5.  Institute of Medicine recommendations for the prevention and control of hepatitis B and C.

Authors:  Abigail E Mitchell; Heather M Colvin; R Palmer Beasley
Journal:  Hepatology       Date:  2010-03       Impact factor: 17.425

6.  Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection.

Authors:  Brian J McMahon; Dana Bruden; Michael G Bruce; Stephen Livingston; Carol Christensen; Chriss Homan; Thomas W Hennessy; James Williams; Daniel Sullivan; Hugo R Rosen; David Gretch
Journal:  Gastroenterology       Date:  2009-11-10       Impact factor: 22.682

7.  Epidemiology and risk factors for hepatitis C in Alaska Natives.

Authors:  Brian J McMahon; Thomas W Hennessy; Carol Christensen; Dana Bruden; Daniel G Sullivan; Chriss Homan; Heike Deubner; Michael G Bruce; Stephen Livingston; James Williams; David R Gretch
Journal:  Hepatology       Date:  2004-02       Impact factor: 17.425

Review 8.  Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies.

Authors:  Rebecca L Morgan; Brittney Baack; Bryce D Smith; Anthony Yartel; Marc Pitasi; Yngve Falck-Ytter
Journal:  Ann Intern Med       Date:  2013-03-05       Impact factor: 25.391

9.  Leveraging the electronic health record to eliminate hepatitis C: Screening in a large integrated healthcare system.

Authors:  Alexander G Geboy; Whitney L Nichols; Stephen J Fernandez; Sameer Desale; Peter Basch; Dawn A Fishbein
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

10.  The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service.

Authors:  Amanda J Wade; Diana M Macdonald; Joseph S Doyle; Adam Gordon; Stuart K Roberts; Alexander J Thompson; Margaret E Hellard
Journal:  PLoS One       Date:  2015-11-12       Impact factor: 3.240
View more
  4 in total

1.  The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals.

Authors:  Lisa Townshend-Bulson; Elena Roik; Youssef Barbour; Dana J T Bruden; Chriss E Homan; Hannah G F Espera; Timothy J Stevenson; Annette M Hewitt; Wileina Rhodes; James E Gove; Julia N Plotnik; Mary M Snowball; John McGilvray; Brenna C Simons; Janet M Johnston; Brian J McMahon
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

2.  The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era in a United States Commercially Insured Population.

Authors:  Nicole D Ferrante; Craig W Newcomb; Kimberly A Forde; Charles E Leonard; Jessie Torgersen; Benjamin P Linas; Sarah E Rowan; David L Wyles; Jay Kostman; Stacey B Trooskin; Vincent Lo Re
Journal:  Open Forum Infect Dis       Date:  2022-09-02       Impact factor: 4.423

3.  Time to HCV Treatment Disfavors Patients Living with HIV/HCV Co-infection: Findings from a Large Urban Tertiary Center.

Authors:  Omar T Sims; Duong N Truong; Kaiying Wang; Pamela A Melton; Kasey Atim
Journal:  J Racial Ethn Health Disparities       Date:  2021-07-12

4.  Psychosocial Obstacles to Hepatitis C Treatment Initiation Among Patients in Care: A Hitch in the Cascade of Cure.

Authors:  Philip R Spradling; Yuna Zhong; Anne C Moorman; Loralee B Rupp; Mei Lu; Stuart C Gordon; Eyasu H Teshale; Mark A Schmidt; Yihe G Daida; Joseph A Boscarino
Journal:  Hepatol Commun       Date:  2020-11-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.